Staphylococcal septic arthritis in rabbits

The article by Wyseben et al provides intriguing insights into the 15 day rabbit Staphylococcus epidermidis infectious arthritis model. However, challenge must be made to their conclusion that injection of cortico- steroids into the infected joint seems to be harm- less, in the setting of infectious arthritis.

Several issues render this model unaccept- able for establishing safety of intra-articular corticosteroid treatment. The real question seems to be what happens to the joint after antibiotic (and intra-articular corticosteroid) treatment. Analysis two weeks, two months, and six months post-treatment would seem impor- tant to identify clinically important effects of intra-articular corticosteroids.

One technical question seems appropriate. How were the section sites selected? The blinding does not seem to have taken place until after the slides were prepared. More detail on the selection process might provide insights as to whether “prime sites” were selected or if the same exact cuts were made in all knees. The study by Wyseben et al provides insights to effect of short-term intra-articular corticosteroids on a low pathogenicity/low infectivity form of infectious arthritis. It is unclear if their conclusion about corticosteroid safety can be extrapolated to organisms of high infectivity/pathogenicity and to clinically significant infection.

BRUCE M ROTHSCHILD
Arthritis Center of Northeast Ohaus,
5500 Market Street, Youngstown,
Ohio 44512, USA

1 Wyseben AJ, Volchek J, Amit M, Robinson D, Boldor I, Nevz T. Treatment of staphylococcal septic arthritis in rabbits by systemic antibiotics and intra-articular corticosteroid treatment. Analysis two weeks, two months, and six months post-treatment would seem important to identify clinically important effects of intra-articular corticosteroids.

Table 1 LMP2/Cf1 genotypic distribution in B27 positive controls and ankylosing spondylitis patients with and without acute anterior uveitis stratified by HLA-DR4

<table>
<thead>
<tr>
<th>Subjects</th>
<th>LMP2/Cf1 Genotypes</th>
<th>AA</th>
<th>AB</th>
<th>BB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total B27+ Controls</td>
<td>4 (7.4%)</td>
<td>25 (46.3%)</td>
<td>25 (46.3%)</td>
<td></td>
</tr>
<tr>
<td>Total B27+ AUA/AS</td>
<td>1 (1.2%)</td>
<td>24 (27.9%)</td>
<td>61 (70.9%)</td>
<td></td>
</tr>
<tr>
<td>B27+ DR4+ Controls</td>
<td>2 (8.7%)</td>
<td>11 (47.6%)</td>
<td>10 (43.5%)</td>
<td></td>
</tr>
<tr>
<td>B27+ DR4+ AUA/AS</td>
<td>1 (3.7%)</td>
<td>13 (49.2%)</td>
<td>21 (76.9%)</td>
<td></td>
</tr>
<tr>
<td>B27+ DR4- AUA/AS</td>
<td>1 (2.3%)</td>
<td>11 (25.6%)</td>
<td>31 (72.1%)</td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05 (LMP2 AA and AB versus LMP2 BB).

Authors’ reply
We thank Dr. Rothschild for his remarks.

The importance of Staphylococcus epider- midis in joint infections is in infected prosthetic joints, where S epidermidis is more common than S aureus. We hypothesised that as a first step, it might be advisable to start the study with not the most virulent bacteria. As stated in the article, we believed that the lower virulence of S epidermidis might give us a better observation of corticosteroid effect. Further research should investigate addi- tional bacterial strains.

Our study was for 15 days. We agree, and in our paper, that future studies should investigate long term effect of this treatment. All joints in the study groups were cut and prepared identically.

A J WYSEBEEK
Department of Internal Medicine B, Assaf Harofeh Medical Centre, Zerifin 70300, Israel


LMP2 polymorphisms and spondyloarthropathies

Dr. Holher and colleagues have examined LMP2 polymorphisms and extra- spinal manifestations in spondyloarthropathies arriving at the conclusion that there is no independent association between LMP2 genotypes and the occurrence of uveitis in HLA-B27 positive patients when stratified for HLA DR4. In my view, this study lacks sufficient power to decide this question definitively. Careful analysis of DR4 positive subjects from the data provided in table 1 of their report shows that 81.25% of patients with acute anterior uveitis carry the LMP2 BB genotype compared with 62.5% of B27 positive controls and 61.5% of spondyloarthropathy patients with axial disease only. This suggests that LMP2 may contribute independently of DR4 to the development of uveitis, though small numbers of DR4 positive patients and controls (eight B27 positive patients, 16 DR4 positive subjects when stratified for HLA DR4) may later develop acute anterior uveitis. This assertion error will vary from study to study. It may be more realistic to compare polymorphisms in people who have already manifest a particular phenotype with an HLA matched control group, rather than with diseased people who have not yet developed that particular phenotype. The authors also cite certain references purported to support the view that DR 4 and LMP2 B are in linkage disequilibrium. The first was based on work in consanguineous ho- mozygous typing cells suggesting linkage disequilibrium between alleles of HLA DR4, TAP2 and LMP7 rather than a population- based study. No formal evidence for linkage disequilibrium between HLA-DR4 and LMP2 B was presented. In contrast, two population-based studies have shown no evidence for linkage disequilibrium between LMP2 alleles and HLA DR4. This is consistent with our own findings in a white population of 282 people where linkage disequilibrium was only noted between LMP2 A and HLA DR3 confirming previous observations. Finally, Holher et al do not actually provide any data to support linkage disequilibrium between DR4 and LMP2 B from their own population. In contrast, our work reinforces the requirement for large population-based studies in view of the necessity for HLA stratification of implicated HLA encoded polymorphisms, particularly in the context of disease phenotypes, if important associations are not to be missed.

WALTER P MAKSYMOWYCH
Rheumatology/CliniC ImmunoLOGY, 562 Heritage Medical Research Centre, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

Author’s reply

Thank you for giving me the opportunity to respond to the letter concerning our paper on LMP2 polymorphisms in patients with ankylosing spondylitis. We agree with the author of the letter that it would be desirable to compare patients that have already manifest a certain disease phenotype (for example, uveitis, peripheral arthritis), however we query the age limit they would suggest. The average age in our study was 47 years, well beyond the 41.5 years, which was the average age in the Maksymowych study. The author fails to provide any epidemiological data on his study population. Acute anterior uveitis was observed only in 27.3% of our patients compared with 45.1% in the Maksymowych study, which may be attributable to ethnic heterogeneity (particularly in Canada), different MHC haplotypes or other still unknown genetic factors in the different populations.

The study by Van Endert was indeed based on work in homozygous typing cell lines, but the authors also cite unpublished own data showing linkage between DR4 and LMP2 in a population of 140 subjects.

Concerning the data provided in the table 1 I think that the numbers are small and the difference in the LMP2 distribution between B27+ DR4+ controls and B27+ DR4+ acute anterior uveitis/ankylosing spondylitis patients just reaches statistical significance before correction for multiple comparisons, which should be done. Unfortunately the given data do not provide any new evidence but just reinforce, as the author states in the last sentence, the requirement for large population-based studies.

T HÖHLER
Langenbeckstr 1, D-55101 Mainz, Germany

Staphylococcal septic arthritis in rabbits

BRUCE M ROTHSCHELD

Ann Rheum Dis 1999 58: 386
doi: 10.1136/ard.58.6.386

Updated information and services can be found at:
http://ard.bmj.com/content/58/6/386.1

These include:

References
This article cites 2 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/58/6/386.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/